Comparison of two-year treatment outcomes between subthreshold micropulse (577 nm) laser and aflibercept for diabetic macular edema



To compare two-year treatment outcomes of subthreshold micropulse (577 nm) laser and aflibercept for diabetic macular edema (DME).

Study design

Retrospective case–control study.


A total 164 eyes in 164 DME patients treated with either micropulse laser (86 eyes) or intravitreal aflibercept monotherapy (78 eyes) were recruited. Main outcome measures included at least five Early Treatment Diabetic Retinopathy Study (ETDRS) letters’ improvement from baseline at 6, 12 and 24 months.


Rescue aflibercept was initiated in 24% of eyes in micropulse laser group. At 6-month visit the aflibercept group achieved a higher percentage of eyes with at least 5-letter visual acuity improvement than micropulse laser group (56% vs 38%, P = 0.044), however, this was not the case at 12-month (45% vs 49%, P = 0.584) and 24-month visits (49% vs 57%, P = 0.227). At 6-month visit the aflibercept group achieved a higher percentage of eyes with at least 10% improvement of central macular thickness (73% vs 49%, P = 0.005), but this was not the case at 12-month (73% vs 70%, P = 0.995) and 24-month visits (85% vs 84%, P = 0.872).


Aflibercept achieved faster and higher rates of anatomical and functional improvement than micropulse laser in DME patients. Long term efficacy of treatment did not result in significant differences between aflibercept monotherapy and micropulse laser in DME patients. Primary treatment of micropulse laser with deferred rescue aflibercept might be the treatment option without reducing the chance of visual improvement in DME eyes.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD. Comorbidity and health care resource use among commercially insured non-elderly patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2015;46:744–51.

    Article  Google Scholar 

  2. 2.

    Bahrami B, Hong T, Gilles MT, Chang A. Anti-VEGF therapy for diabetic eye diseases. Asia Pac J Ophthalmol (Phila). 2017;6:535–45.

    CAS  Google Scholar 

  3. 3.

    Ziemssen F, Wachtlin J, Kuehlewein L, Gamulescu MA, Bertelmann T, Feucht N, et al. Intravitreal ranibizumab therapy for diabetic macular edema in routine practice: two-year real-life data from a non-interventional Multicenter Study in Germany. Diabetes Ther. 2018;9:2271–89.

    CAS  Article  Google Scholar 

  4. 4.

    Kourlaba G, Relakis J, Mahon R, Kalogeropoulou M, Pantelopoulou G, Kousidou O, et al. Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema. Cost Eff Resour Alloc. 2016;14:7.

    Article  Google Scholar 

  5. 5.

    Mekjavic JP, Balciuniene VJ, Ceklic L, Ernest J, Jamrichova Z, Nagy ZZ, et al. The burden of macular diseases in central and eastern Europe-implications for healthcare systems. Value Health Reg Issues. 2019;19:1–6.

    Article  Google Scholar 

  6. 6.

    Fong DS, Luong TQ, Contreras R, Jimenez JJ, Custis PH, Patel V, et al. Treatment patterns and 2-year vision outcomes with bevacizumab in diabetic macular edema: an analysis from a large US Integrated Health Care System. Retina. 2018;38:1830–8.

    CAS  Article  Google Scholar 

  7. 7.

    Zas M, Cotic M, Wu A, Wu L. Macular laser photocoagulation in the management of diabetic macular edema: Still relevant in 2020? Taiwan J Ophthalmol. 2020;10:87–94.

    Article  Google Scholar 

  8. 8.

    Vujosevic S, Martini F, Longhin E, Convento E, Cavarzeran F, Midena E. Subthreshold micropulse yellow laser versus subthreshold micropulse infrared laser in center-involving diabetic macular edema: morphologic and functional safety. Retina. 2015;35:1594–603.

    Article  Google Scholar 

  9. 9.

    Scholz P, Altay L, Fauser S. A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther. 2017;34:1528–55.

    Article  Google Scholar 

  10. 10.

    Abouhussein MA, Gomaa AR. Aflibercept plus micropulse laser versus aflibercept monotherapy for diabetic macular edema: 1-year results of a randomized clinical trial. Int Ophthalmol. 2020;40:1147–54.

    Article  Google Scholar 

  11. 11.

    Kanar HS, Arsan A, Altun A, Aki SF, Hacisalihoglu A. Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial. Indian J Ophthalmol. 2020;68:145–51.

    Article  Google Scholar 

  12. 12.

    Fazel F, Bagheri M, Golabchi K, Jahanbani AH. Comparison of subthreshold diode laser micropulse therapy versus conventional photocoagulation laser therapy as primary treatment of diabetic macular edema. J Curr Ophthalmol. 2016;28:206–11.

    Article  Google Scholar 

  13. 13.

    Chhablani J, Alshareef R, Kim DT, Narayanan R, Goud A, Mathai A. Comparison of different settings for yellow subthreshold laser treatment in diabetic macular edema. BMC Ophthalmol. 2018;18:168.

    Article  Google Scholar 

  14. 14.

    Inagaki K, Ohkoshi K, Ohde S, Deshpande GA, Ebihara N, Murakami A. Comparative efficacy of pure yellow (577-nm) and 810-nm subthreshold micropulse laser photocoagulation combined with yellow (561–577-nm) direct photocoagulation for diabetic macular edema. Jpn J Ophthalmol. 2015;59:21–8.

    CAS  Article  Google Scholar 

  15. 15.

    Akkaya S, Acikalin B, Dogan YE, Coban F. Subthreshold micropulse laser versus intravitreal anti-VEGF for diabetic macular edema patients with relatively better visual acuity. Int J Ophthalmol. 2020;13:1606–11.

    Article  Google Scholar 

  16. 16.

    Nicolo M, Musetti D, Traverso CE. Yellow micropulse laser in diabetic macular edema: a short-term pilot study. Eur J Ophthalmol. 2014;24:885–9.

    Article  Google Scholar 

  17. 17.

    Donati MC, Murro V, Mucciolo DP, Giorgio D, Cinotti G, Virgili G, et al. Subthreshold yellow micropulse laser for treatment of diabetic macular edema: comparison between fixed and variable treatment regimen. Eur J Ophthalmol. 2020.

    Article  PubMed  Google Scholar 

  18. 18.

    Vujosevic S, Bottega Casciano EM, Pilotto E, Convento E, Midena E. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina. 2010;30:908–16.

    Article  Google Scholar 

  19. 19.

    Otani T, Kishi S, Maruyama Y. Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol. 1999;127:688–93.

    CAS  Article  Google Scholar 

  20. 20.

    Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130:972–9.

    CAS  Article  Google Scholar 

  21. 21.

    Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123:2376–85.

    Article  Google Scholar 

  22. 22.

    Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118:615–25.

    Article  Google Scholar 

  23. 23.

    Blindbaek SL, Peto T, Grauslund J. How do we evaluate the role of focal/grid photocoagulation in the treatment of diabetic macular edema? Acta Ophthalmol. 2018.

    Article  PubMed  Google Scholar 

  24. 24.

    Vujosevic S, Martini F, Convento E, Longhin E, Kotsafti O, Parrozzani R, et al. Subthreshold laser therapy for diabetic macular edema: metabolic and safety issues. Curr Med Chem. 2013;20:3267–71.

    CAS  Article  Google Scholar 

  25. 25.

    Gao X, Xing D. Molecular mechanisms of cell proliferation induced by low power laser irradiation. J Biomed Sci. 2009;16:4.

    Article  Google Scholar 

  26. 26.

    Midena E, Bini S, Martini F, Enrica C, Pilotto E, Micera A, et al. Changes of aqueous humor müller cells' biomarkers in human patients affected by diabetic macular edema after subthreshold micropulse laser treatment. Retina. 2020;40(1):126–34.

    Article  PubMed  Google Scholar 

  27. 27.

    Vujosevic S, Gatti V, Muraca A, Brambilla M, Villani E, Nucci P, et al. Optical coherence tomography angiography changes after subthreshold micropulse yellow laser in diabetic macular edema. Retina. 2020;40(2):312–21.

    Article  PubMed  Google Scholar 

  28. 28.

    Chen G, Tzekov R, Li W, Jiang F, Mao S, Tong Y. subthreshold micropulse diode laser versus conventional laser photocoagulation for diabetic macular edema: a meta-analysis of randomized controlled trials. Retina. 2016;36:2059–65.

    CAS  Article  Google Scholar 

  29. 29.

    Miller K, Fortun JA. Diabetic macular edema: current understanding, pharmacologic treatment options, and developing therapies. Asia Pac J Ophthalmol (Phila). 2018;7:28–35.

    CAS  Google Scholar 

  30. 30.

    Ohkoshi K, Yamaguchi T. Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients. Am J Ophthalmol. 2010;149:133–9.

    Article  Google Scholar 

  31. 31.

    Mansouri A, Sampat KM, Malik KJ, Steiner JN, Glaser BM. Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness. Eye (Lond). 2014;28:1418–24.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Frank Hiu Ping Lai.

Ethics declarations

Conflicts of interest

F. H. P. Lai, None; R. P. S. Chan, None; A. C. H. Lai, None; S. Tsang, None; T. T. Y. Woo, None; R. F. Lam, None; C. Y. F. Yuen, None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Corresponding Author: Frank Hiu Ping Lai

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lai, F.H.P., Chan, R.P.S., Lai, A.C.H. et al. Comparison of two-year treatment outcomes between subthreshold micropulse (577 nm) laser and aflibercept for diabetic macular edema. Jpn J Ophthalmol (2021).

Download citation


  • Diabetic macular edema
  • Micropulse
  • Laser
  • Aflibercept